Thank you all for your continued support.  

We have received the following update from MHRA:

'Data is being sought regarding both the frequency of haematological monitoring and the criteria that is currently used for stopping clozapine across different regulatory jurisdictions. This will include the recent changes in the US regulation. In addition, similar work is now also being undertaken across Europe which may provide a more comprehensive data set than that from the UK alone but this European assessment will take some time to conclude. As part of this work, the proposals included in the joint expert statement from the European Clozapine task force (Verdoux et al., 2025) are being considered. We anticipate receiving the data in the summer.'

We will keep on until the necessary improvements are made with clozapine use.